Spanish drugmaker Almirall, which is building up its business in skin treatments, could be interested in acquiring dermatology assets from Canada’s Valeant Pharmaceuticals, the head of the Barcelona-based company said on Monday. Valeant is looking at divesting various products as it tries to reduce its massive debt load, […]
Click here to view original web page at www.businessinsider.com